Physician profile
Emma J Taylor
NPI 1356407076
$4,066.63
in general payments reported to CMS, 2019-2025
19 companies · $828 in 2025
The $828 reported for 2025 was more than what 88% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.59 · 2020: $135 · 2021: $150 · 2022: $1,909 · 2023: $256 · 2024: $714 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,900.11 | 2021-2022 | |
| Genzyme Corporation | $607.54 | 2020-2025 | |
| Abbvie INC. | $442.92 | 2021-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $215.29 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $137.07 | 2020-2024 | Adbry |
| Lilly USA, LLC | $123.82 | 2023-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $113.05 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $72.64 | 2024-2025 | |
| Galderma Laboratories, L.P. | $68.19 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.23 | 2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $63.60 | 2020 | |
| Arcutis Biotherapeutics, INC. | $50.50 | 2024-2025 | Zoryve |
| Merz North America, INC. | $33.99 | 2023 | |
| Organon LLC | $32.99 | 2025 | Vtama |
| Janssen Biotech, INC. | $32.65 | 2025 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.27 | 2024 | Opzelura |
| Amgen INC. | $25.32 | 2023 | Otezla |
| Verrica Pharmaceuticals INC. | $24.73 | 2025 | Ycanth |
| Dermira, INC. | $22.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.